Nakajima, K., T. Kanda, M. Takaishi, T. Shiga, K. Miyoshi, H. Nakajima, R. Kamijima, M. Tarutani, J. M. Benson, M. M. Elloso, L. L. Gutshall, M. F. Naso, Y. Iwakura, J. DiGiovanni, and S. Sano. 2011. Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model. J. Immunol. 186: 4481–4489.
After the publication of this article, we were informed that a reagent used in the studies was inadvertently provided in error.
The anti-mouse IL-23p19 Ab (CNTO 6163) provided to us by Centocor was subsequently determined to actually be CNTO 3913, an Ab to mouse IL-12/23p40, which neutralizes both IL-12 and IL-23. CNTO 3913 was also intentionally utilized in the studies and appropriately noted as an anti–IL-12/23p40 Ab. We included IL-23p19 Ab results in Figs. 3, 4, and 5. Not unexpectedly, we did not find significant differences between anti–IL-23p19 and anti–IL-12/23p40 effects. However, we did state conclusions within the text that designated the pharmacological effects to IL-23. This should be corrected to more accurately describe the effects as IL-12/23p40 mediated.
To address the Ab identity error, we have reproduced the studies with the proper CNTO 6163 Ab and provide here updated Figs. 3, 4, and 5. We believe that the main conclusions of the article remain true because there were significant differences between IL-23p19 and IL-17A inhibition.
We deeply regret this inadvertent error and apologize for any inconvenience this may have caused.